Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Forte Biosciences, Inc. - Common Stock (NQ:FBRX)

28.93 -0.30 (-1.03%)
Streaming Delayed Price Updated: 1:27 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Forte Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Announces Pricing of $75 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Results and Provides Clinical Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences to Host R&D Day December 3, 2024
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting
From On behalf of Concerned Stockholders of Forte
Via Business Wire
News headline image
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom
From On behalf of Concerned Stockholders of Forte
Via Business Wire
News headline image
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
From On behalf of Concerned Stockholders of Forte
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
From Forte Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.